ARVINAS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ARVINAS, INC. (ARVN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$16.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-04
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$10.10M.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$6.80M.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $16.00M.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$100.00K.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$1.70M.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$21.20M, a 222.54% decline from fiscal 2023.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $17.30M, a 14.36% decline from fiscal 2022.
- ARVINAS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $20.20M, a 27.60% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$16.90M 10-Q · filed 2026-08-04 | -$900.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$6.80M 10-Q · filed 2026-05-11 | $9.20M derived: sum of 2 quarters · filed 2026-05-11 | $9.10M derived: sum of 3 quarters · filed 2026-05-11 | -$7.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.90M derived: sum of 2 quarters · filed 2026-02-24 | -$900.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.70M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$16.90M derived: sum of 2 quarters · filed 2026-08-04 | -$17.70M 10-Q · filed 2025-11-05 | -$22.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$16.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$17.60M 10-Q · filed 2026-08-04 | -$22.50M derived: sum of 3 quarters · filed 2026-08-04 | -$24.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$800.00K 10-Q · filed 2026-05-11 | -$5.70M derived: sum of 2 quarters · filed 2026-05-11 | -$8.10M derived: sum of 3 quarters · filed 2026-05-11 | -$6.30M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$7.30M derived: sum of 2 quarters · filed 2026-02-24 | -$5.50M derived: sum of 3 quarters · filed 2026-02-24 | -$21.20M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$600.00K derived: sum of 2 quarters · filed 2025-11-05 | -$16.30M 10-Q · filed 2025-11-05 | -$15.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$13.90M 10-Q · filed 2025-08-06 | -$12.60M derived: sum of 3 quarters · filed 2026-02-24 | $4.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$15.70M 10-Q · filed 2025-05-01 | -$14.40M derived: sum of 2 quarters · filed 2026-02-24 | $2.20M derived: sum of 3 quarters · filed 2026-02-24 | $10.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $17.90M derived: sum of 2 quarters · filed 2026-02-24 | $26.10M derived: sum of 3 quarters · filed 2026-02-24 | $17.30M 10-K · filed 2026-02-24 |
| 2023-09-30 | $16.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $24.80M derived: sum of 2 quarters · filed 2024-10-30 | $16.00M 10-Q · filed 2024-10-30 | $41.20M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $8.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$600.00K 10-Q · filed 2024-07-30 | $24.60M derived: sum of 3 quarters · filed 2025-02-11 | $32.30M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | -$8.80M 10-Q · filed 2024-05-07 | $16.40M derived: sum of 2 quarters · filed 2025-02-11 | $24.10M derived: sum of 3 quarters · filed 2025-02-11 | $27.00M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $32.90M derived: sum of 2 quarters · filed 2025-02-11 | $35.80M derived: sum of 3 quarters · filed 2025-02-11 | $20.20M 10-K · filed 2025-02-11 |
| 2022-09-30 | $7.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $10.60M derived: sum of 2 quarters · filed 2023-11-07 | -$5.00M 10-Q · filed 2023-11-07 | $30.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$12.70M 10-Q · filed 2023-08-08 | $22.80M derived: sum of 3 quarters · filed 2024-02-27 | $23.00M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$15.60M 10-Q · filed 2023-05-05 | $19.90M derived: sum of 2 quarters · filed 2024-02-27 | $20.10M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | $35.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $35.70M derived: sum of 2 quarters · filed 2024-02-27 | $27.90M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$7.60M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$7.80M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $12.80M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |